Post on 26-Feb-2018
7/25/2019 Improving Access to Innovator Drugs
1/12
Improving Access to InnovatDrugsHepatitis C and lessons from HIV
January 26 - Bangkok
7/25/2019 Improving Access to Innovator Drugs
2/12
All people in need should have access
to Gilead medicines, regardless of
where they live or their economicstatus
7/25/2019 Improving Access to Innovator Drugs
3/12
Our Model of Treatment Expansion
Tiered Pricing
Branded drugs available
at deeply discounted prices
Generic Licensing
Partnerships with generic manufacturers
to produce high-quality, low-cost medicines
Drug Registration
Working with networkof business partners
to submit regulatory
dossiers on a country
by country basis
Relevant Data
Broad clinical trials acrossbroad patient populations;
local clinical trials where
appropriate; key
demonstration projects
Partnerships &
Health Systems StrengtheningAgreements with non-profit
service providers and on the
ground medical education and
training
Product D
Targeted donattreatment initia
underserved
A dedicated business unit working to improve treatment access in 130 count
7/25/2019 Improving Access to Innovator Drugs
4/12
Guiding Principles
PartnershipCollaborate with public
sector and other
companies
AdaptabilityHeed lessons learned;
continually innovate
SustainabilityDesign access efforts for
the long term
ResponsibilityFocus where needs
are greatest
7/25/2019 Improving Access to Innovator Drugs
5/12
More Than a Decade of Progress
2006 2011 20132003 201
Gilead H
medicine
million pthe devel
world
Gilead expands HIV
Access Program
through licensing
agreements withIndian generic
manufacturers
Gilead launches its
HIV Access Program
Gilead becomes the first HIV
manufacturer to sign a licensing
agreement with the Medicines
Patent Pool
2014
Gileads first hepatitis C medicine
becomes available in Egypt, the
highest-burden country in the world,less than a year after its U.S. approval
Gilead expands its hepatitis C licensing
agreements to include more companies,
more countries and more products
Gilead licenses its
hepatitis C medicines to
India-based generic
manufacturers
Gilead is ranked #1 by the
Access to Medicine Index for
patents/licensing and
equitable pricing
2012
7/25/2019 Improving Access to Innovator Drugs
6/12
Generic Competition Has Reduced Prices
Driven by competition among licensed generic manufacturers, the
cost of Gilead HIV medicines has fallen by 80%
30 133413
703
1,400
2,400 2,900
5,400
7,3008,000
$17.00
$12.42$12.42
$8.25
$6.50
$5.50
$4.49 $ 4. 00 $ 4. 00$3.60
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
LowestPrice(PerPatient/M
onth)
PatientsReached(Thousa
nds)
Year
7/25/2019 Improving Access to Innovator Drugs
7/12
Patient Access to ARVs
More than half of patients on antiretroviral therapy in the developi
world are now receiving Gilead medicines
Generic drug
manufacturers account
for 98% of Gilead HIVmedicines prescribed in
developing countries
Includes patients receiving Vireadfor hepatitis B. Viread is approved for both HIV
and chronic hepatitis B virus infection
7/25/2019 Improving Access to Innovator Drugs
8/12
Hepatitis C Treatment Expansion Approach
Significantbrandedmedicinediscounts
Supportingcountry &
NGOprograms
Businesspartnerships
Investment inresearch
Policydevelopment
Genericmanufacturing
For 101 resource poor countries
that represent >50% of the
global hepatitis C burdenTo strengthen hepatitis C
and care, and to reach hi
populations
Partners register medicin
regulatory authorities, co
distribution, manage sup
and conduct safety repor
Including local clinical trials and
demonstration projects
Investing in initiatives to foster
global support for greater
action against hepatitis C
Flat pricing in all low-income and nearly alllower-middle-income countries; tiered pricing (b
per capita) for all other middle-income countries
negotiated on an individual country basis
STRATEGIES
7/25/2019 Improving Access to Innovator Drugs
9/12
Hepatitis C Generic Licensing Partners
Eleven International Partners
Produce generic hepatitis C medicines for
101 resource poor countries
Three In-Country Partners
Produce generic hepatitis C medicines fo
their home countries
7/25/2019 Improving Access to Innovator Drugs
10/12
Egypt has the highest HCV prevalence in the world
nearly 15%, by some estimates.
The partnership:
Ministry of Health implementing ambitious national HCV
treatment program, providing care through government
clinics and hospitals
Gilead provides branded Sovaldi to Egyptian Ministry of
Health at a significantly reduced price
Gilead supports MoH-led HCV medical education and
prevention efforts
As of December 2015, more than 150,000 patients have
initiated treatment with Sovaldi
Will also begin providing Harvoni in January 2016
Access in Action: Egypt
Launch of Egypts nationa
hepatitis C treatment initiati
October 2014
7/25/2019 Improving Access to Innovator Drugs
11/12
Egypt has the highest HCV prevalence in the
world
nearly 15%, by some estimates.
Access in Action: Georgia
Approximately 7% of Georgians are infected with HCV
the third-highest prevalence in the world.
The partnership:
Ministry of Health, the U.S. Centers for Disease Control and
Prevention and Gilead collaborating to eliminate hepatitis C in
Georgia
Goal is to demonstrate the impact of widespread HCV
screening and universal treatment on a national scale
Ministry of Health to lead and implement the program
U.S. CDC to provide technical support and guidance
Gilead to provide branded Sovaldi and Harvoni at no cost to
program with aims to initially treat 5,000 patients in its first year
with the eventual goal of treating up to 20,000 patients eachyear
A patient participating in the pro
May 2015
7/25/2019 Improving Access to Innovator Drugs
12/12
Q&A